{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:31:50Z","timestamp":1775079110261,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41409-025-02681-4","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:15:44Z","timestamp":1756570544000},"page":"1496-1498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab"],"prefix":"10.1038","volume":"60","author":[{"given":"Cathelijne","family":"Fokkema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein K.","family":"Appelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Veldhoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Spelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-2671","authenticated-orcid":false,"given":"Bronno","family":"van der Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meriam","family":"Grootes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Wester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"de Pater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-7979","authenticated-orcid":false,"given":"Paula F.","family":"Ypma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annoek E. C.","family":"Broers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"2681_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"2681_CR2","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2009;27:4767\u201373.","journal-title":"J Clin Oncol"},{"key":"2681_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00277-020-04376-w","volume":"100","author":"L Wang","year":"2021","unstructured":"Wang L, Xiang H, Yan Y, Deng Z, Li H, Li X, et al. Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis. Ann Hematol. 2021;100:563\u201373.","journal-title":"Ann Hematol"},{"key":"2681_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41409-018-0152-2","volume":"53","author":"CC Chua","year":"2018","unstructured":"Chua CC, Lim HY, Chai KL, Ong J, Sim S, Wood C, et al. Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma. Bone Marrow Transpl. 2018;53:1116\u201323.","journal-title":"Bone Marrow Transpl"},{"key":"2681_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/bmt.2015.236","volume":"51","author":"R Silvennoinen","year":"2016","unstructured":"Silvennoinen R, Anttila P, S\u00e4ily M, Lundan T, Heiskanen J, Siitonen TM, et al. A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transpl. 2016;51:372\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2681_CR6","unstructured":"https:\/\/publicatie.hematologienederland.nl\/richtlijnen\/multipel-myeloom\/. 2024."},{"key":"2681_CR7","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","volume":"34","author":"E Terpos","year":"2020","unstructured":"Terpos E, Engelhardt M, Cook G, Gay F, Mateos M-V, Ntanasis-Stathopoulos I, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia 2020;34:2000\u201311.","journal-title":"Leukemia"},{"key":"2681_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390:301\u201313.","journal-title":"N Engl J Med"},{"key":"2681_CR9","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","volume":"106","author":"C Hulin","year":"2021","unstructured":"Hulin C, Offner F, Moreau P, Roussel M, Belhadj K, Benboubker L, et al. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study. Haematologica 2021;106:2257\u201360.","journal-title":"Haematologica"},{"key":"2681_CR10","first-page":"174.e1","volume":"29","author":"S Chhabra","year":"2023","unstructured":"Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, et al. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transpl Cell Ther. 2023;29:174.e1\u2013e10.","journal-title":"Transpl Cell Ther"},{"key":"2681_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40164-018-0119-4","volume":"7","author":"X Ma","year":"2018","unstructured":"Ma X, Wong SW, Zhou P, Chaulagain CP, Doshi P, Klein AK, et al. Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Exp Hematol Oncol. 2018;7:27.","journal-title":"Exp Hematol Oncol"},{"key":"2681_CR12","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3324\/haematol.2022.282269","volume":"108","author":"B Dhakal","year":"2023","unstructured":"Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, et al. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica 2023;108:2249\u201354.","journal-title":"Haematologica"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02681-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:20:40Z","timestamp":1762183240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02681-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2681"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02681-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BvdH has received honoraria for data safety monitoring board membership from Intergroupe Francophone du My\u00e9lome (IFM). RW receives honoraria from Sanofi and Janssen. PS receives honoraria and\/or research funding from Amgen, Celgene, Janssen Pharmaceuticals, Karyopharm. AB receives honoraria from Amgen, Bristol-Myers Squibb, Celgene, and Janssen Pharmaceuticals. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}